Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of HELP is 42.0 and suggests 451% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre